Perspective reports VMT01 melanoma data and NANETS NET updates, Phase 3 targeted for 2027

Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) announced updated interim results on November 6, 2026 from its Phase 1/2a trial of lapemelanotide zapixetar (VMT01) in advanced melanoma, presented as a poster at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting in Phoenix, Arizona.¹

The data covered 20 patients who received at least one monotherapy treatment of lapemelanotide as of a September 18, 2026 data cutoff, across three dose cohorts going up to cumulative doses of 4.5, 9, and 15 mCi, given in three treatments of 1.5, 3.0, and 5.0 mCi every eight weeks.¹ At the focus dose of 3.0 mCi, two of eight enrolled patients had objective partial responses, one of whom remained in partial response about 40 weeks after the first treatment, and the disease control rate was 75%, including two patients with long-lasting disease stabilization.¹ Across all 20 monotherapy patients, no dose-limiting toxicities, treatment-related serious adverse events, or discontinuations due to adverse events were reported, and Grade 3 or higher TEAEs occurred in five patients (25%), none considered treatment-related.¹

This follows the company's November 5 presentation at the NANETS 2026 symposium on bamzireotide navoxetan (VMT-α-NET) in SSTR2-expressing neuroendocrine tumors. Among 57 GEP-NET patients whose target lesions all expressed SSTR2, progression free survival was 75% at 18 months, disease control occurred in 92% of 38 Cohort 2 patients and all 17 Cohort 3 patients, and responses were seen in 37% of Cohort 2 and 47% of Cohort 3 patients.² CEO Thijs Spoor said the company is incorporating these findings into discussions with regulators on the design of a registration-enabling study, targeting an end-of-Phase 2 meeting in the first quarter of 2027, with FDA feedback expected to enable initiation of a Phase 3 study in 2027.²